Identification of Genetic Variants Associated With Response to Statin Therapy
Authors:
- 1 September 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 29 (9) , 1310-1315
Abstract
Objective— The purpose of this study was to test the association between polymorphisms in genes involved in either LDL cholesterol (LDL-C) metabolism or statin pharmacokinetics and LDL-C reduction with statins. Methods and Results— 49 tagging and candidate polymorphisms in 9 genes were genotyped in 1507 post-ACS subjects randomized to atorvastatin or pravastatin. Two polymorphisms (rs7412, rs429358) that define the ε2, ε3, and ε4 isoforms of apolipoprotein E were significantly associated with percent reduction in LDL-C with atorvastatin (ε2 carriers 53.8%, ε3/ε3 48.1%, and ε4 carriers 46.4%, respectively, P =0.00039) and replicated in the pravastatin arm (ε2 carriers 22.1%, ε3/ε3 21.8%, and ε4 carriers 16.6%, respectively, P =0.00038). The proportion of subjects achieving an LDL-C ≤70 mg/dL at day 30 was higher for ε2 than ε4 carriers ( P =1.3×10 −5 ). In the pravastatin group, the triallelic rs2032582 variant (G2677T/A) in ABCB1 was associated with the percent reduction in LDL-C (GG 23.3%, non-G heterozygote 20.3%, and non-G homozygote 17.4%, P =0.042). Conclusion— Carriers of APOE ε2 versus ε4 had significantly greater LDL-C reduction with atorvastatin and with pravastatin, and more frequently achieved a guideline-recommended LDL-C ≤70 mg/dL. Polymorphisms in triallelic G2677T/A variant in ABCB1 were associated with the degree of LDL-C lowering with pravastatin.Keywords
This publication has 28 references indexed in Scilit:
- Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) CohortCirculation: Cardiovascular Genetics, 2009
- Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose ResponseCirculation: Cardiovascular Genetics, 2008
- Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin TreatmentCirculation, 2008
- Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humansNature Genetics, 2008
- Heritability of Cardiovascular and Personality Traits in 6,148 SardiniansPLOS Genetics, 2006
- Effect ofABCB1(MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjectsBritish Journal of Clinical Pharmacology, 2006
- An association study of 43 SNPs in 16 candidate genes with atorvastatin responseThe Pharmacogenomics Journal, 2005
- Pharmacogenetic Study of Statin Therapy and Cholesterol ReductionJAMA, 2004
- Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary SyndromesNew England Journal of Medicine, 2004
- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ, 2003